UB-311

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).

UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1374092844 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.